ABSTRACT
Age-related macular degeneration (AMD) is the leading cause of vision loss in senior adults. The disease can be categorized into two types: wet AMD and dry AMD. Wet AMD, also known as exudative or neovascular AMD, is less common but more severe than dry AMD and is responsible for 90% of the visual impairment caused by AMD and affects 20 million people worldwide. Current treatment options mainly involve biologics that inhibit the vascular endothelial growth factor or complement pathways. However, these treatments have limitations such as high cost, injection-related risks, and limited efficacy. Therefore, new therapeutic targets and strategies have been explored to improve the outcomes of patients with AMD. A promising approach is the use of small-molecule drugs that modulate different factors involved in AMD pathogenesis, such as tyrosine kinases and integrins. Small-molecule drugs offer advantages, such as oral administration, low cost, good penetration, and increased specificity for the treatment of wet and dry AMD. This review summarizes the current status and prospects of small-molecule drugs for the treatment of wet AMD. These advances are expected to support the development of effective and targeted treatments for patients with AMD.
Subject(s)
Macular Degeneration , Humans , Macular Degeneration/drug therapy , Small Molecule Libraries/pharmacology , Animals , Angiogenesis Inhibitors/therapeutic use , Angiogenesis Inhibitors/pharmacology , Angiogenesis Inhibitors/administration & dosage , Wet Macular Degeneration/drug therapy , Drug Development/methods , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/metabolismABSTRACT
Chiral metal oxide nanostructures have received tremendous attention in nanotechnological applications owing to their intriguing chiroptical and magnetic properties. Current synthetic methods mostly rely on the use of amino acids or peptides as chiral inducers. Here, we report a general approach to fabricate chiral metal oxide nanostructures with tunable magneto-chiral effects, using block copolymer (BCP) inverse micelle and R/S-mandelic acid (MA). Diverse chiral metal oxide nanostructures are prepared by the selective incorporation of precursors within micellar cores followed by the oxidation process, exhibiting intense chiroptical properties with a g-factor up to 7.0 × 10-3 in the visible-NIR range for the Cr2O3 nanoparticle multilayer. The BCP inverse micelle is found to inhibit the racemization of MA, allowing MA to act as a chiral dopant that imparts chirality to nanostructures via hierarchical chirality transfer. Notably, for paramagnetic nanostructures, magneto-chiroptical modulation is realized by regulating the direction of the external magnetic field. This BCP-driven approach can be extended to the mass production of chiral nanostructures with tunable architectures and optical activities, which may provide insights into the development of chiroptical functional materials.
ABSTRACT
Transparent conducting electrodes (TCEs) have attracted considerable attention towards the development of flexible optoelectronic devices. In this study, mixed-dimensional TCEs are fabricated based on the two-dimensional graphene and one-dimensional electrospun metal fiber that can address the shortcomings of each electrode. In comparison with other TCEs, the Ag fiber/graphene hybrid electrodes exhibited a highly stable morphology (67% lower peak-to-valley ratio), low sheet resistance (approximately 11 Ω/sq), high transmittance (approximately 94%), high oxidation stability with excellent flexibility, and outstanding chemical stability. The multiple functionalities of the transparent and flexible hybrid structure highlight its potential for applications in emerging electronics and highly stable optoelectronics.
